# VIM-positive Pseudomonas aeruginosa - the pre-SAMPAN study.

No registrations found.

**Ethical review** Positive opinion **Status** Recruiting

Health condition type -

**Study type** Observational non invasive

## **Summary**

#### ID

NL-OMON24069

Source

Nationaal Trial Register

**Brief title**Pre-SAMPAN

**Health condition** 

VIM-positive Pseudomonas aeruginosa carriage

## **Sponsors and support**

**Primary sponsor:** Not applicable

Source(s) of monetary or material Support: ZonMw

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

The main study endpoint is finding positive body sites of VIM-positive P. aeruginosa, other than the standard surveillance culture sites.

## **Secondary outcome**

Secondary endpoints are patient characteristics favouring specific body sites being colonized by VIM-positive Pseudomonas aeruginosa.

# **Study description**

### **Background summary**

Currently, throat and rectum samples are the standard body sites for surveillance cultures to identify patients with Verona Integron-encoded Metallo- $\beta$ -lactamase (VIM)-positive Pseudomonas aeruginosa (VIM-PA). Pseudomonas aeruginosa in general favours moist areas. Therefore, it is likely that VIM-PA has the ability to colonize other body sites as well. It is unknown, however, to which extent patients are also culture positive at other body sites, for example the navel, the ears, or between the toes. Inclusion of additional body sites may increase the detection rate.

## **Study objective**

VIM-positive Pseudomonas aeruginosa can be found in other body sites besides throat and rectum, which are currently used as the standard surveillance culture sites.

## Study design

1

## **Contacts**

#### **Public**

Erasmus MC University Medical Center Dr. Juliëtte A. Severin

010 70 34188

#### Scientific

Erasmus MC University Medical Center Dr. Juliëtte A. Severin

010 70 34188

# **Eligibility criteria**

## Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria: All living patients aged >18 years old, known to be carrying VIM-PA or formerly carrying VIM-PA, with a signed consent sheet.

## **Exclusion criteria**

A potential subject who meets any of the following criteria will be excluded from participation in this study: no informed consent.

# Study design

## **Design**

Study type: Observational non invasive

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 17-08-2021

Enrollment: 20

Type: Anticipated

## **IPD** sharing statement

Plan to share IPD: No

## **Ethics review**

Positive opinion

Date: 17-08-2021

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL9674

Other METC Erasmus MC: MEC-2021-0525

# **Study results**